TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: CRAMPS Trial: Controlled Randomized Trial Assessing Maternal Post-partum Pain With Suppositories
Brief Summary: This trial will evaluate whether the routine use of belladonna/opium (B\&O) suppositories improve patients' self-reported pain control in the first 24-hours after delivery.


Options:
A: Arm Label: Binder Arm; Type: EXPERIMENTAL; Interventions: Device: Abdominal binder | Arm Label: Standard of Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DEVICE; Name: Abdominal binder; Assigned to Arm(s): Binder Arm
B: Arm Label: Post-partum primi and multiparous women; Type: EXPERIMENTAL; Interventions: Device: Leboride | Arm Label: Post-partum women that have already begun breast feeding; Type: EXPERIMENTAL; Interventions: Device: Leboride | Intervention Type: DEVICE; Name: Leboride; Assigned to Arm(s): Post-partum primi and multiparous women, Post-partum women that have already begun breast feeding
C: Arm Label: Glycerin suppository; Type: PLACEBO_COMPARATOR; Interventions: Drug: Glycerin Suppository | Arm Label: Belladonna and opioid suppository; Type: EXPERIMENTAL; Interventions: Drug: Belladonna and opioid suppository | Intervention Type: DRUG; Name: Belladonna and opioid suppository; Assigned to Arm(s): Belladonna and opioid suppository | Intervention Type: DRUG; Name: Glycerin Suppository; Assigned to Arm(s): Glycerin suppository
D: Arm Label: Black tea bag; Type: EXPERIMENTAL; Interventions: Other: Warm water soaked Black Tea Bags | Arm Label: ice packs; Type: ACTIVE_COMPARATOR; Interventions: Other: Frozen perineal pad | Intervention Type: OTHER; Name: Frozen perineal pad; Assigned to Arm(s): ice packs | Intervention Type: OTHER; Name: Warm water soaked Black Tea Bags; Assigned to Arm(s): Black tea bag

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Double-blind, Randomized, Placebo-controlled, Safety And Efficacy Study Of Once Daily Controlled Release Pregabalin In The Treatment Of Patients With Fibromyalgia (Protocol A0081245)
Brief Summary: The purpose of this study is to evaluate the efficacy and safety of a controlled release formulation of pregabalin administered once daily as compared to placebo in the treatment of fibromyalgia. All patients will receive pregabalin; half of the patients will receive placebo at some point in the study.


Options:
A: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Pregabalin | Intervention Type: DRUG; Name: Pregabalin; Assigned to Arm(s): 1
C: Arm Label: Pregabalin; Type: EXPERIMENTAL; Interventions: Drug: pregabalin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pregabalin; Assigned to Arm(s): Pregabalin | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: All Enrolled Participants; Type: N/A; Interventions: Drug: Standard of care for treatment of osteoarthritis (OA) of knee(s) | Intervention Type: DRUG; Name: Standard of care for treatment of osteoarthritis (OA) of knee(s); Assigned to Arm(s): All Enrolled Participants

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect of Liraglutide on Body Weight in Non-diabetic Obese Subjects or Overweight Subjects With Co-morbidities: A Randomised, Double-blind, Placebo Controlled, Parallel Group, Multi-centre, Multinational Trial With Stratification of Subject to Either 56 or 160 Weeks of Treatment Based on Pre-diabetes Status at Randomisation
Brief Summary: This trial is conducted in Africa, Asia, Europe, Oceania, North America and South America.

The aim of this clinical trial is to evaluate the potential of liraglutide to induce and maintain weight loss over 56 weeks in obese subjects or overweight subjects with co-morbidities. Furthermore, the aim is to investigate the long term potential of liraglutide to delay the onset of type 2 diabetes in subjects diagnosed with pre-diabetes at baseline.

Based on body mass index (BMI) and pre-diabetes status, subjects will be randomised to either 68 weeks (56 weeks of randomised treatment followed by a 12 week re-randomised treatment period) or 160 weeks of treatment (160 week treatment will only be applicable to subjects with pre-diabetes status at baseline).


Options:
A: Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68); Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68); Type: EXPERIMENTAL; Interventions: Drug: placebo | Arm Label: Liraglutide Placebo, no Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Arm Label: Liraglutide 3.0mg, Pre-diabetes; Type: EXPERIMENTAL; Interventions: Drug: liraglutide | Arm Label: Liraglutide Placebo, Pre-diabetes; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide 3.0mg (week56-68) | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide 3.0mg (week0-56)/Liraglutide Placebo (week56-68), Liraglutide Placebo, no Pre-diabetes | Intervention Type: DRUG; Name: liraglutide; Assigned to Arm(s): Liraglutide 3.0mg, Pre-diabetes | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Liraglutide Placebo, Pre-diabetes
B: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pioglitazone | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Pioglitazone; Type: ACTIVE_COMPARATOR; Interventions: Drug: pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
D: Arm Label: Pioglitazone; Type: EXPERIMENTAL; Interventions: Drug: Pioglitazone | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Pioglitazone; Assigned to Arm(s): Pioglitazone | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Nutrition: Evaluation of an Educational Touchscreen Computer Program for Use in a Spanish-speaking Population of Caregivers of Young Children (APA Phase II)
Brief Summary: The investigators are recruiting participants for a randomized controlled trial to evaluate the usability and educational value of a nutrition education touchscreen computer program targeting Spanish-speaking Latina caregivers of children 2 and under.

Participants will be randomized to the intervention group - use the computer program and the control group - do not use the program. They will be asked basic demographic questions, nutrition knowledge questions and computer users will be asked usability questions.

Objectives are

1. Evaluate the subjective and objective usability of the touchscreen computer.
2. Determine whether health knowledge on nutrition topics is enhanced through the use of the computer modules.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Behavioral: dietary education | Intervention Type: BEHAVIORAL; Name: dietary education; Assigned to Arm(s): A
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Diabetes Care for Korean Americans | Intervention Type: BEHAVIORAL; Name: Diabetes Care for Korean Americans; Assigned to Arm(s): 1
C: Arm Label: Health Literacy; Type: EXPERIMENTAL; Interventions: Behavioral: Health literacy, health message | Intervention Type: BEHAVIORAL; Name: Health literacy, health message; Assigned to Arm(s): Health Literacy
D: Arm Label: Computer Use; Type: EXPERIMENTAL; Interventions: Other: Computer Use | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Computer Use; Assigned to Arm(s): Computer Use

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Infant Nutrition: Evaluation of an Educational Touchscreen Computer Program for Use in a Spanish-speaking Population of Caregivers of Young Children (APA Phase II)
Brief Summary: The investigators are recruiting participants for a randomized controlled trial to evaluate the usability and educational value of a nutrition education touchscreen computer program targeting Spanish-speaking Latina caregivers of children 2 and under.

Participants will be randomized to the intervention group - use the computer program and the control group - do not use the program. They will be asked basic demographic questions, nutrition knowledge questions and computer users will be asked usability questions.

Objectives are

1. Evaluate the subjective and objective usability of the touchscreen computer.
2. Determine whether health knowledge on nutrition topics is enhanced through the use of the computer modules.


Options:
A: Arm Label: Computer Use; Type: EXPERIMENTAL; Interventions: Other: Computer Use | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Computer Use; Assigned to Arm(s): Computer Use
B: Arm Label: Routine health education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Routine health education | Arm Label: Nutrition education package; Type: EXPERIMENTAL; Interventions: Behavioral: Nutrition education, Behavioral: Routine health education | Intervention Type: BEHAVIORAL; Name: Nutrition education; Assigned to Arm(s): Nutrition education package | Intervention Type: BEHAVIORAL; Name: Routine health education; Assigned to Arm(s): Nutrition education package, Routine health education
C: Arm Label: Doula; Type: EXPERIMENTAL; Interventions: Behavioral: Doula | Arm Label: Usual Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Doula; Assigned to Arm(s): Doula
D: Arm Label: Essential Health Care (EHC) only; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Mass media | Arm Label: EHC + Micronutrient Powders; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Arm Label: EHC + BCC; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Behavioral: Mass media | Arm Label: EHC + BCC + Micronutrient powders; Type: EXPERIMENTAL; Interventions: Behavioral: EHC + BCC, Dietary Supplement: Micronutrient powders, Behavioral: Mass media | Intervention Type: BEHAVIORAL; Name: EHC + BCC; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders | Intervention Type: DIETARY_SUPPLEMENT; Name: Micronutrient powders; Assigned to Arm(s): EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders | Intervention Type: BEHAVIORAL; Name: Mass media; Assigned to Arm(s): EHC + BCC, EHC + BCC + Micronutrient powders, EHC + Micronutrient Powders, Essential Health Care (EHC) only

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Azithromycin for Preventing the Development of Upper Respiratory Tract Illness Into Lower Respiratory Tract Symptoms in Children and Oral Corticosteroids for Treating Episodes of Significant Lower Respiratory Tract Symptoms in Children
Brief Summary: This protocol is comprised of two separate, but linked, clinical trials for treating preschool-aged children with recurrent severe episodes of wheezing. The first study (APRIL) will try to prevent wheezing illness from developing using azithromycin. If a wheezing illness does occur, the second trial (OCELOT) will try to decrease the severity of symptoms using oral corticosteroids.


Options:
A: Arm Label: Azithromycine; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycine | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Azithromycin; Type: EXPERIMENTAL; Interventions: Drug: Azithromycin | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Azythromycin (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Prednisolone | Arm Label: Azythromycin (APRIL) and Placebo (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Azithromycin, Drug: Placebo Prednisolone | Arm Label: Placebo (APRIL) and Prednisolone (OCELOT); Type: EXPERIMENTAL; Interventions: Drug: Prednisolone, Other: Placebo Azithromycin | Arm Label: Placebo (APRIL) and Placebo (OCELOT); Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo Azithromycin, Drug: Placebo Prednisolone | Intervention Type: DRUG; Name: Azithromycin; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Azythromycin (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Prednisolone (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: OTHER; Name: Placebo Azithromycin; Assigned to Arm(s): Placebo (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Prednisolone (OCELOT) | Intervention Type: DRUG; Name: Placebo Prednisolone; Assigned to Arm(s): Azythromycin (APRIL) and Placebo (OCELOT), Placebo (APRIL) and Placebo (OCELOT)
D: Arm Label: Clarithromycin; Type: EXPERIMENTAL; Interventions: Drug: Clarithromycin, Drug: VCD induction therapy | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: VCD induction therapy | Intervention Type: DRUG; Name: Clarithromycin; Assigned to Arm(s): Clarithromycin | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: VCD induction therapy; Assigned to Arm(s): Clarithromycin, Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of Oxygen Therapy in Acute Myocardial Infarction (AVOID - Air Verses Oxygen In myocarDial Infarction Study)
Brief Summary: - Aim

The AVOID (Air Verses Oxygen In myocardial infarction) trial is designed to determine if the withholding of routine oxygen therapy in patients with acute heart attack leads to reduced heart damage compared to the current practice of routine inhaled oxygen for all patients.

- Background

There is evidence supporting and refuting the current practice of providing oxygen to all patients with acute heart attack. A recent summary of clinical trials suggested that oxygen may increase the degree of heart damage during heart attack. It also highlighted that the few trials into oxygen therapy were performed before the use of modern medications and procedures to treat heart attack and that further studies were urgently needed, using contemporary practices.

- Design

A total of 334 patients will participate in this randomized controlled trial. Patients in this study will receive the best current management and care for their condition. Patients will be randomized to routine pre-hospital care with oxygen therapy vs pre-hospital care without oxygen therapy. Patients will then receive standard hospital care, aside from allocated oxygen or no oxygen therapy. The primary outcome measure of heart damage will be investigated using routine blood tests. With additional information gathered from other aspects of routine heart care including coronary angiogram, electrocardiograms and complications of hospital stay. Patients will be followed up at 6 months to determine any longer term effects of treatment.


Options:
A: Arm Label: Oxygen therapy; Type: OTHER; Interventions: Other: Oxygen therapy | Arm Label: No oxygen therapy; Type: OTHER; Interventions: Other: No oxygen therapy | Intervention Type: OTHER; Name: Oxygen therapy; Assigned to Arm(s): Oxygen therapy | Intervention Type: OTHER; Name: No oxygen therapy; Assigned to Arm(s): No oxygen therapy
B: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Device: AO Therapy (aqueous oxygen) | Intervention Type: DEVICE; Name: AO Therapy (aqueous oxygen); Assigned to Arm(s): 2
C: Arm Label: Nasal oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Nasal oxygen | Arm Label: Nasal Air; Type: PLACEBO_COMPARATOR; Interventions: Drug: Regular nasal air | Intervention Type: DRUG; Name: Nasal oxygen; Assigned to Arm(s): Nasal oxygen | Intervention Type: DRUG; Name: Regular nasal air; Assigned to Arm(s): Nasal Air
D: Arm Label: No oxygen; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Oxygen; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): Oxygen

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial of Oxygen Therapy in Acute Myocardial Infarction (AVOID - Air Verses Oxygen In myocarDial Infarction Study)
Brief Summary: - Aim

The AVOID (Air Verses Oxygen In myocardial infarction) trial is designed to determine if the withholding of routine oxygen therapy in patients with acute heart attack leads to reduced heart damage compared to the current practice of routine inhaled oxygen for all patients.

- Background

There is evidence supporting and refuting the current practice of providing oxygen to all patients with acute heart attack. A recent summary of clinical trials suggested that oxygen may increase the degree of heart damage during heart attack. It also highlighted that the few trials into oxygen therapy were performed before the use of modern medications and procedures to treat heart attack and that further studies were urgently needed, using contemporary practices.

- Design

A total of 334 patients will participate in this randomized controlled trial. Patients in this study will receive the best current management and care for their condition. Patients will be randomized to routine pre-hospital care with oxygen therapy vs pre-hospital care without oxygen therapy. Patients will then receive standard hospital care, aside from allocated oxygen or no oxygen therapy. The primary outcome measure of heart damage will be investigated using routine blood tests. With additional information gathered from other aspects of routine heart care including coronary angiogram, electrocardiograms and complications of hospital stay. Patients will be followed up at 6 months to determine any longer term effects of treatment.


Options:
A: Arm Label: Oxygen therapy; Type: OTHER; Interventions: Other: Oxygen therapy | Arm Label: No oxygen therapy; Type: OTHER; Interventions: Other: No oxygen therapy | Intervention Type: OTHER; Name: Oxygen therapy; Assigned to Arm(s): Oxygen therapy | Intervention Type: OTHER; Name: No oxygen therapy; Assigned to Arm(s): No oxygen therapy
B: Intervention Type: DRUG; Name: Nitrous Oxide; Assigned to Arm(s): N/A
C: Arm Label: 1; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: standard operating management | Intervention Type: PROCEDURE; Name: standard operating management; Assigned to Arm(s): 2
D: Arm Label: A; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Arm Label: B; Type: ACTIVE_COMPARATOR; Interventions: Drug: Oxygen | Intervention Type: DRUG; Name: Oxygen; Assigned to Arm(s): A, B

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Cognitive-Behavioral Treatment for Patients With Mild Alzheimer's Dementia: A Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether a comprehensive cognitive-behavioral therapy-based, multi-component treatment programme is effective in the treatment of neuropsychiatric symptoms of patients with mild Alzheimer's dementia.


Options:
A: Arm Label: Cognitive behavioural therapy; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Cognitive behavioural therapy | Arm Label: Tai chi; Type: ACTIVE_COMPARATOR; Interventions: Other: Tai chi | Arm Label: Postural control exercise; Type: ACTIVE_COMPARATOR; Interventions: Other: Postural control exercise | Intervention Type: BEHAVIORAL; Name: Cognitive behavioural therapy; Assigned to Arm(s): Cognitive behavioural therapy | Intervention Type: OTHER; Name: Tai chi; Assigned to Arm(s): Tai chi | Intervention Type: OTHER; Name: Postural control exercise; Assigned to Arm(s): Postural control exercise
B: Arm Label: Cognitive Behavioral Therapy (CBT); Type: EXPERIMENTAL; Interventions: Behavioral: Comprehensive, CBT-based, multi-component treatment | Arm Label: Treatment as usual (TAU); Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Treatment as usual | Intervention Type: BEHAVIORAL; Name: Comprehensive, CBT-based, multi-component treatment; Assigned to Arm(s): Cognitive Behavioral Therapy (CBT) | Intervention Type: BEHAVIORAL; Name: Treatment as usual; Assigned to Arm(s): Treatment as usual (TAU)
C: Arm Label: observational; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Exercise group; Type: EXPERIMENTAL; Interventions: Other: Exercise intervention | Intervention Type: OTHER; Name: Exercise intervention; Assigned to Arm(s): Exercise group
D: Arm Label: Fall prevention standard of care; Type: OTHER; Interventions: Other: Evidence-based tailored fall prevention | Arm Label: Control; Type: OTHER; Interventions: Other: Usual care | Intervention Type: OTHER; Name: Evidence-based tailored fall prevention; Assigned to Arm(s): Fall prevention standard of care | Intervention Type: OTHER; Name: Usual care; Assigned to Arm(s): Control

Answer: B